Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide and Azacitidine for MDS and CMML
NCT00118196Phase 2Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Apr 2005
- Primary completion
- Aug 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of arsenic trioxide and azacitidine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Medical University of South Carolina. Primary endpoint: Overall Response Rate at 113 days. Started Apr 2005; status: terminated.
02
Drugs
arsenic trioxideazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00118196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118196.